1. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.
- Author
-
Tomas E and Habener JF
- Subjects
- Amino Acid Sequence, Animals, Blood Vessels drug effects, Blood Vessels metabolism, Cytoprotection drug effects, Cytoprotection physiology, Glucagon-Like Peptide 1 chemistry, Glucagon-Like Peptide 1 metabolism, Glucagon-Like Peptide-1 Receptor, Heart drug effects, Hepatocytes drug effects, Hepatocytes metabolism, Humans, Liver drug effects, Liver metabolism, Models, Biological, Models, Theoretical, Molecular Sequence Data, Peptide Fragments metabolism, Peptide Fragments pharmacology, Protein Processing, Post-Translational physiology, Receptor, Insulin metabolism, Receptors, Glucagon genetics, Receptors, Glucagon metabolism, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide 1 physiology, Insulin pharmacology, Receptor, Insulin physiology, Receptors, Glucagon physiology
- Abstract
GLP-1 (9-36)amide is the cleavage product of GLP-1(7-36) amide, formed by the action of diaminopeptidyl peptidase-4 (Dpp4), and is the major circulating form in plasma. Whereas GLP-1(7-36)amide stimulates glucose-dependent insulin secretion, GLP-1(9-36)amide has only weak partial insulinotropic agonist activities on the GLP-1 receptor, but suppresses hepatic glucose production, exerts antioxidant cardioprotective actions and reduces oxidative stress in vasculature tissues. These insulin-like activities suggest a role for GLP-1 (9-36)amide in the modulation of mitochondrial functions by mechanisms independent of the GLP-1 receptor. In this paper, we discuss the current literature suggesting that GLP-1(9-36)amide is an active peptide with important insulin-like actions. These findings have implications in nutrient assimilation, energy homeostasis, obesity, and the use of Dpp4 inhibitors for the treatment of diabetes., (Copyright (c) 2009 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF